What Continuous Glucose Monitoring Data Can and Cannot Tell You

Continuous glucose monitoring earns its strongest evidence in one place: people who take insulin, especially those at risk of dangerous lows, where it reliably improves glucose control and reduces time spent in hypoglycemia. Outside that group the picture gets softer fast. The device measures something real, but it measures glucose in the fluid between cells, not in blood, and it produces so many numbers that the line between signal and noise becomes the whole game. A sensor that shows you a beautiful graph has told you what your interstitial glucose did. Whether seeing it makes you healthier is a separate question, and the answer depends almost entirely on who you are. This article is educational and not medical advice; for your own care, talk with a clinician who knows you.

What is a CGM actually measuring?

A continuous glucose monitor is a small sensor worn under the skin that estimates glucose in the fluid between cells every few minutes and streams the readings to a phone. The word estimate matters. It approximates blood glucose, and the two track closely most of the time. But interstitial glucose lags behind blood glucose, because the sugar has to diffuse out of the capillaries before the sensor sees it, and that lag grows when glucose moves fast. So the gap is widest exactly when the number is changing quickest, right after a meal or during a rapid drop. This is physics, not a defect, and better sensors model around it. But it means a single reading is a modeled guess, usually good and occasionally off, most likely off during the steep parts of the curve people find alarming. When someone shows you one dramatic spike from a trace, the honest first question is whether the blood was really there.

What does the strong evidence actually cover?

The firmest ground is glucose control in people who use insulin. For type 1 diabetes, and for type 2 treated with intensive insulin, randomized trials have shown that wearing a CGM improves measured glucose control and cuts time spent low, compared with finger-stick testing alone. That matters, because severe hypoglycemia is frightening and the thing many patients fear most. A device that lets you see a fall coming and act before it becomes an emergency is doing something valuable.

Notice the shape of the claim, though. What the trials reliably move is glucose control and time in hypoglycemia, which are themselves markers, not the hard complications. Most CGM trials are not long or large enough to measure heart attacks or kidney failure directly. So the precise reading is that CGM improves the markers we use to predict complications and reduces the immediate harm of severe lows. That is plenty without inflating it into something it has not shown.

Why is time in range a better number than it looks, and worse?

Time in range, the share of the day your glucose sits within a target band, is the metric CGM made possible, and it is genuinely informative. A single HbA1c gives you an average over three months, and an average hides its tails. Two people with the same HbA1c can live very different days: one steady inside the band, the other swinging between highs and lows that cancel out on paper. Time in range exposes that difference, which is why clinicians who manage insulin value it. The caution is that it is still a surrogate, and a young one. It tracks roughly with HbA1c and correlates with the small-vessel complications, but the trials linking a specific target to fewer complications are still maturing. Use it as a working goal and a way to compare today with last month, not as proof that nudging the number across a threshold prevents a defined amount of harm.

Where do the weaker claims come from?

The most ambitious claims involve people without diabetes wearing a sensor to optimize health, and here the evidence thins to almost nothing. The reasoning sounds plausible: see your spikes, change your diet, and surely you end up healthier. But almost every step in that chain is an assumption rather than a finding. A glucose rise after a meal in a person with a normal pancreas is usually a healthy organ doing its job, not a warning, and we lack good evidence that chasing a flatter line in a metabolically healthy person changes future risk of disease.

There is also a measurement problem hiding in plain sight. When glucose bounces inside a narrow normal range, much of what the sensor shows is noise, the ordinary error of the device amplified by a y-axis zoomed in tight enough to make small wiggles look like drama. A common trap is treating every bump on a densely sampled trace as a meaningful event, when the device was never accurate enough at that resolution to say so. None of this makes the curiosity foolish or the people building on it bad-faith; the instinct to measure is a good one. The gap is that the trials showing this kind of self-tracking improves long-term health in healthy people do not yet exist. The right posture is interest without conviction.

How should you read a CGM claim?

Start by asking who was studied. A result proven in people on insulin does not automatically transfer to people managing diet alone, and a finding in healthy volunteers tells you little about someone with established diabetes. The population carries the claim, and claims travel badly across populations.

Then ask what outcome was measured and over how long. A change in a glucose metric over a few weeks is an early signal about the machinery, not proof of a complication prevented over a decade. Watch for the quiet slide from "the sensor showed a spike" to "this food is harming you," with nothing in between to earn the upgrade. The first is a number on a screen; the second is a claim about your future that the number alone cannot support.

Finally, respect the resolution of the tool. CGM is excellent at showing trends, direction, and the dangerous extremes it was built to catch, and far weaker at telling one normal reading from another a few points away. Trust the alarms at the edges and discount the small wiggles in the middle. The device is most trustworthy where the stakes are highest, and least trustworthy in exactly the region where it is most often oversold.

Working in diabetes, I have learned to ask the same thing of any new stream of data: does it change what we do, and for whom. CGM answers that cleanly for people on insulin and far less cleanly elsewhere. A graph that moves tells you the body responded. Whether you are better off is the next question, and the best reading of CGM data never lets the first answer pretend to be the second.